T

TG Therapeutics

D
TGTX
USD
0.7
(2.5735%)
Market Closed
120,789.00
Volume
0.37
EPS
-
Div Yield
41.029
P/E
4,319,565,522.30
Market Cap
Today
7.9512%
1 Week
11.333%
1 Month
30.802%
6 Months
62.493%
12 Months
157.856%
Year To Date
63.445%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
M
MYOV
(%)
USD
C
CRVS
-0.01
(-0.1135%)
USD
J
JNCE
0.085
(5.3125%)
USD
P
PBYI
-0.02
(-0.6547%)
USD
K
KPTI
0.0008
(0.0909%)
USD
I
INCY
1.47
(1.8173%)
USD
B
BLUE
-0.0615
(-14.0764%)
USD

Title:
TG Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Do you need help or have a question?
Contact Us